Unknown

Dataset Information

0

Healthcare and Economic Impact of Lung Perfusion Scintigraphy in Patients Affected by Acute Pulmonary Embolism.


ABSTRACT: Acute pulmonary embolism (APE) is a cardiovascular emergency, representing the main cause of mortality, morbidity, and hospitalisation in Europe. We aim to evaluate the economic and healthcare impact of lung perfusion scintigraphy (LPS) used in patients with suspected APE, in the event of non-conclusive or contraindicated computed tomography pulmonary angiography (CTPA). We considered two alternative healthcare processes for APE diagnosis, with and without LPS. We performed a cost analysis with the aim of evaluating the average direct healthcare costs for diagnosis, risk assessment, and treatment of APE. We used data from a monocentric trial. Our economic model showed that the strategy with LPS was preferable in terms of costs. The average per-patient costs for the diagnosis and treatment of the acute phase of PE in low-risk patients with a non-conclusive or not-executable CTPA, with and without LPS, are EUR 2145.25 and EUR 4912.45, respectively. LPS is a simple, quick, and economic examination, useful in this setting of patients not only for an early diagnosis but also to exclude APE, demonstrating an advantage in terms of healthcare resources. To the best of our knowledge, this study is the first to analyse the economic and healthcare impact of the use of LPS in the diagnostic pathway of suspected APE.

SUBMITTER: Rubini G 

PROVIDER: S-EPMC8230672 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2009-09-01 | GSE13535 | GEO
| S-EPMC9562549 | biostudies-literature
| S-EPMC9724819 | biostudies-literature
| S-EPMC2970864 | biostudies-literature
| S-EPMC9940751 | biostudies-literature
| S-EPMC6290752 | biostudies-literature
| S-EPMC4543115 | biostudies-other
| S-EPMC6312023 | biostudies-literature
| S-EPMC3913120 | biostudies-literature
| S-EPMC10163473 | biostudies-literature